Skip to main content
. Author manuscript; available in PMC: 2017 Jun 1.
Published in final edited form as: Ann Intern Med. 2016 Aug 2;165(8):533–542. doi: 10.7326/M16-0547

Figure 2. Cases of incident composite diabetes during longitudinal follow-up.

Figure 2

Shown are the proportion of participants who developed incident composite diabetes during follow-up. Eligible participants did not have any type of diabetes at baseline (the time of imaging), and had ≥3 years of follow-up. Panel (A) shows all 725 eligible participants (110 with NFAT and 625 without adrenal tumors), where participants with NFAT had subclinical hypercortisolism excluded using either a 1mg DST or a 24h UFC. Panel (B) shows only those participants with NFAT who had subclinical hypercortisolism excluded using a 1mg DST≤1.8 mcg/dL (73 eligible), and panel (C) shows only those participants with NFAT who had subclinical hypercortisolism excluded using a 24h UFC<50 mcg (50 eligible). Panel (D) depicts an exploratory analysis, whereby participants who were initially excluded from the main analysis due to potential subclinical hypercortisolism were included, and compared with all the eligible participants without adrenal tumors and with NFAT to assess incident composite diabetes.

Blue squares and lines indicate participants with no adrenal tumors.

Red diamonds and lines indicate participants with NFAT.

Black circles and lines indicate participants with adrenal tumors and subclinical hypercortisolism.

NFAT= “non-functional” adrenal tumor